Skip to main content

Table 2 Patient characteristics.

From: A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

  Men with an elevated PSA not undergoing subsequent biopsy N = 259 Men who received a biopsy N = 370
   Complete marker and DRE data N = 262 Missing marker or DRE N = 108
   No Cancer N = 179 Cancer N = 83 No Cancer N = 76 Cancer N = 32
Age at screening (years) 64 (59, 67) 63 (59, 67) 65 (61, 69) 65 (60, 67) 65 (61, 68)
Total PSA 3.75 (3.12, 4.80) N = 228 4.23 (3.36, 5.58) 4.86 (3.81, 7.23) - -
Free PSA 0.88 (0.67, 1.15) N = 228 1.01 (0.77, 1.32) 0.96 (0.67, 1.36) - -
Intact PSA 0.38 (0.27, 0.56) N = 228 0.45 (0.34, 0.63) 0.50 (0.33, 0.75) - -
Human Kallikrein 2 0.061 (0.038, 0.094) N = 216 0.061 (0.036, 0.090) 0.088 (0.050, 0.132) - -
Number of biopsy cores - 12 (10, 12) 12 (10, 12) 11 (6, 12) 10 (6, 12)
Clinical T Stage      
   T1 - - 31 (37%) - 13 (41%)
   T2 - - 39 (47%) - 12 (38%)
   T3 - - 8 (10%) - 1 (3%)
   Missing - - 5 (6%) - 6 (19%)
Biopsy Gleason Grade      
   <= 6 - - 33 (40%) - 17 (53%)
   7 - - 33 (40%) - 11 (34%)
   >= 8 - - 12 (14%) - 3 (9%)
   Missing - - 5 (6%) - 1 (3%)
  1. All values are median (interquartile range) or frequency (proportion).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us